- Dotz Nano (DTZ) enters a co-development, supply and licensing collaboration with Greece-based company Theracell Labs
- A subsidiary of NASDAQ-listed global biotech Orgenesis, Theracell is a developer of cell and gene therapy devices, treatments and processing systems
- Under the agreement, Dotz and Theracell will aim to jointly develop technology solutions to create an identification standard to tag patient-derived cells
- If the collaboration results in the successful development of a commercialised product, Theracell will be granted a licence to manufacture, market, distribute and sell the results
- Shares in Dotz end the day 8.96 per cent in the green at 36.5 cents
Dotz Nano (DTZ) has entered a co-development, supply and licensing collaboration with Greece-based company Theracell Labs.
A subsidiary of NASDAQ-listed global biotech Orgenesis, Theracell is a developer of cell and gene therapy devices, treatments and processing systems.
Under the agreement, Dotz and Theracell will work together to jointly develop technology solutions to create an identification standard to tag patient-derived cells.
Dotz’s end-to-end authentication technology will be used to mark disposable bioprocessing consumables by using on and in-product tagging techniques.
Theracell has committed to minimum purchase orders of US$5 million (A$6.73 million) for the first 12 months for the supply of Dotz-tagged disposable bioprocessing consumables.
If the collaboration results in the successful development of a commercialised product and all necessary regulatory approvals are obtained, Theracell will be granted an exclusive, perpetual global licence to manufacture, market, distribute and sell the results of the collaboration.
Further, Theracell will be required to pay Dotz five per cent of the net revenue from the sale.
Dotz has noted there is no certainty the collaboration will result in the successful development of a commercialised product.
The collaboration is open-ended and can be terminated by either company in the event of a breach by giving 30 days written notice.
The agreement is also subject to KPIs required to be satisfied by Dotz which are yet to be agreed on. The failure of the KPIs will enable Theracell to terminate the agreement.
“This collaboration with a global biotech leader is testament to the innovation and versatility of our end-to-end authentication technology,” Chairman Bernie Brookes commented.
“Dotz’s variety of advanced materials and in-depth and extensive knowledge in the
development of novel taggants and fluorescent materials allow us to offer advanced traceability solutions for bio-imaging applications that increase treatment precision and efficiency.”
Shares in Dotz ended the day 8.96 per cent in the green at 36.5 cents.